english
Immunotherapy of triple-negative breast cancer with cathepsin-D-targeting antibodies. Journal of ImmunoTherapy of Cancer; 2019, in press.

Immunotherapy of triple-negative breast cancer with cathepsin-D-targeting antibodies. Journal of ImmunoTherapy of Cancer; 2019, in press.

En savoir plus
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. 13/08/2018

En savoir plus
CD73: a new biomarker in triple-negative breast cancer. Transl Cancer Res 2018

CD73: a new biomarker in triple-negative breast cancer. Transl Cancer Res 2018. 05/2018

En savoir plus
J Nucl Med. 2018 Apr 19. pii: jnumed.118.208611. doi: 10.2967/jnumed.118.208611. [Epub ahead of print]

Anti-MISRII radiolabeled antibodies: new tools for a theranostic...

En savoir plus
Antioxid Redox Signal. 2018 Mar 22. doi: 10.1089/ars.2017.7267. [Epub ahead of print]

Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy...

En savoir plus
Oncoimmunology, 2018, in press

Personal history of infections and immunotherapy: unexpected links...

En savoir plus
Kidney International, 2018 Feb 15. pii: S0085-2538(18)30001-2

Increased degradation of ATP is driven by memory regulatory T cells in kidney transplantation tolerance

En savoir plus
EMBO Mol Med. 2018 Feb 9. pii: e7918. doi: 10.15252/emmm.201707918. [Epub ahead of print]

Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy...

En savoir plus
Mol Cell. 2018 Feb 15;69(4):594-609.e8. doi: 10. 1016/j. molcel. 2018.01.023.

Mitochondrial MDM2 regulates respiratory complex I activity independently of p53

En savoir plus
Nucleic Acids Res. 2018 Jan 24. doi: 10.1093/nar/gky034.

Cell-cycle regulation of non-enzymatic functions of the Drosophila methyltransferase PR-Set7.

En savoir plus
© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés